Publications
Hedgehog Pathway Inhibition Improves Lung Function and Reduces Lung Fibrosis in Patients with IPF: Results from a Randomized, Double-blind, Placebo-controlled Phase 2 Trial of ENV-101
Presented at the 22nd International Colloquium on Lung and Airway Fibrosis 2024
T. M. Maher,1 J. G. Goldin,2 A. DiFrancesco,3 M. de los Rios,3 C. Quito,3 S. Kim,3 E. Bizjak,3 J. Hood3
1. PCCM, Keck School of Medicine of USC, Los Angeles, CA, United States 2. David Geffen School of Medicine at UCLA, Santa Monica, CA, United States 3. Endeavor BioMedicines, San Diego, CA, United States
ENV-101, A Novel Hedgehog Inhibitor, Increases Lung Function, and Reduces Lung Fibrosis in Patients With Idiopathic Pulmonary Fibrosis: Results From a Randomized, Double-blind, Placebo-controlled Phase 2 Trial
Presented at the American Thoracic Society 2024 International Conference
T. M. Maher1, J. G. Goldin2, A. DiFrancesco3, M. de los Rios3, C. Quito3, S. Kim3, P. A. Frohna3, J. Hood3
1. PCCM, Keck School of Medicine of USC, Los Angeles, CA, United States 2. David Geffen School of Med At UCLA, Santa Monica, CA, United States 3. Endeavor BioMedicines, San Diego, CA, United States